The European Centre for Disease Prevention and Control (ECDC) has recorded a worrying trend in healthcare-associated infections caused by the bacterium Klebsiella pneumoniae. According to the centre's latest reports, from 2019 to 2025, the number of bloodstream infections caused by resistant strains of this bacterium increased by 72%. This means that the EU's goal of reducing such cases by 5% by 2030 is effectively moving further out of reach, with the real trend moving in the opposite direction.
Mortality up to 70% and resistance to new drugs
Infections related to Klebsiella pneumoniae pose a particular threat to hospitalized patients. Estimates suggest that the mortality rate for such diseases ranges from 40% to 70%. Laboratory analyses show that certain strains of the bacterium have developed resistance to almost all known antibiotics, including the newest treatments. Christian Giske, head of the ECDC research department, called the situation with resistant Klebsiella pneumoniae the most alarming of all superbug data collected in Europe over the past year.
Part of a wider antimicrobial resistance problem
The increase in cases is only the visible part of a broader phenomenon: antimicrobial resistance, the ability of bacteria and fungi to adapt to the drugs intended to destroy them. It is estimated that about 35,000 people die each year due to such infections in the EU, Iceland, and Norway. Giske characterizes this as a serious threat to public health, emphasizing that the problem affects not just individual hospitals, but the entire regional healthcare system.
Call for intensified infection control
Since the bacterium can be transmitted from patient to patient, the ECDC is calling on hospitals to strengthen infection prevention and control. Necessary measures include meticulous hand hygiene, correct use of gloves and other personal protective equipment, as well as thorough cleaning and disinfection of facilities. Such approaches have already proven effective in combating another dangerous hospital bacterium, MRSA: in 2025, the number of bloodstream infections caused by it was 19% lower than in 2019, exceeding the EU target of a 15% reduction by 2030.
Why Klebsiella is harder to manage than MRSA
However, according to Giske, the situation with Klebsiella is more complex. The bacterium resides in the human gut and can form significant reservoirs there, meaning measures that were effective against MRSA will not necessarily produce a comparable result in the fight against Klebsiella pneumoniae. To contain its spread, hospitals will have to adhere to even stricter infection safety rules than those applied previously.
Context: other outbreaks in Europe
The superbug situation fits into the broader context of infectious threats in the region. Recall that in May 2026, an outbreak of the Andes hantavirus strain occurred on the Dutch cruise ship MV Hondius, leading to several deaths. Five Ukrainian citizens were on board the vessel — no symptoms of the disease were detected in them. Both episodes highlight that Europe's healthcare system is facing simultaneous pressure from several persistent and highly lethal pathogens.